Will AI Replace Allergists? What the Data Shows

A 13% automation risk. That's one of the lowest numbers you'll find among medical specialties, and it tells a story about why some doctors sleep a little easier at night when the AI headlines roll in.

But before you relax too much — your documentation workflow is about to change dramatically, and the allergists who ignore that shift may find themselves falling behind colleagues who embrace it. The 13% number is real, but it's also misleading if you read it without the context of what AI is doing to medicine as a whole.

The Numbers Tell a Reassuring Story

Allergists currently face an overall AI exposure of 38% with an automation risk of just 13% as of 2025. [Fact] That places this specialty firmly in the medium exposure category — well below the average for healthcare occupations that involve heavy diagnostic work. Compare that to radiology, where automation risk now exceeds 40% for image-interpretation-focused subspecialties, or pathology, where AI is reshaping primary diagnostic workflows. Allergy and immunology benefits structurally from being more than a diagnostic-imaging specialty.

The task-level breakdown reveals exactly why.

Interpreting allergy test results and immunological panels sits at 55% automation. [Fact] AI diagnostic tools can now cross-reference IgE levels, skin test reactions, and component-resolved diagnostics against vast databases of allergen profiles. They're getting genuinely good at pattern recognition — identifying complex multi-allergen sensitivities that might take a human clinician longer to piece together. Component-resolved diagnostics in particular benefits from AI because the data is structured, high-dimensional, and inherently pattern-matching, which plays to neural network strengths. A 2024 study from a major academic immunology center reported that an AI-augmented review of ImmunoCAP panels reduced interpretation time by approximately 40% with no measurable loss of diagnostic accuracy. [Claim]

Documenting patient histories and treatment outcomes has reached 68% automation. [Fact] This is actually the highest-impact area for AI in allergy practice. Ambient clinical documentation tools can now listen to patient consultations and generate structured SOAP notes, track immunotherapy progress across visits, and flag patients who may need protocol adjustments. Vendors like Abridge, Suki, and DAX Copilot are deploying widely across allergy practices, and the productivity returns are concrete: allergists using these tools commonly report 1-2 hours per day of reclaimed time, which translates either into more patient capacity or shorter clinic days — a meaningful quality-of-life upgrade in a specialty where burnout is rising in line with broader physician trends.

But here's where AI hits a wall: performing skin prick tests and administering immunotherapy is only 10% automated. [Fact] These are hands-on clinical procedures that require physical skill, real-time patient observation, and immediate response capability. When a patient has an unexpected reaction during an allergy shot, the response needs to be instantaneous and involve clinical judgment that AI simply cannot replicate. The procedural moat here is durable because the stakes are high: anaphylaxis can become fatal within minutes, and no liability insurer or regulatory body is signing off on autonomous AI-administered immunotherapy in any realistic timeframe.

Why Allergists Are Particularly Well Protected

Allergy and immunology sits in a sweet spot for AI resilience. The specialty combines three elements that are individually hard to automate and nearly impossible to automate together: hands-on procedural work, complex diagnostic reasoning across multiple body systems, and long-term patient relationships that depend on trust.

Consider what an allergist actually does in a typical week. You're reading skin prick tests where the interpretation depends on the specific patient's dermatographism, medications, and skin condition. You're adjusting immunotherapy doses based on a combination of objective markers and subjective patient reports. You're counseling a parent whose child just had an anaphylactic episode at school about how to manage their environment — a conversation that requires empathy, cultural sensitivity, and practical knowledge of school systems, often involving 504 plans or IEP coordination that varies by district.

None of that is going away.

The long-term immunotherapy relationship is particularly protective. Allergists often follow patients for 3-5 years through allergen-specific immunotherapy, building up trust and clinical familiarity that compounds across visits. That relationship asset is hard for AI to substitute for and even harder for new market entrants — whether they're tech-driven telemedicine platforms or AI-only diagnostic services — to displace.

The BLS projects +5% growth for allergists through 2034. [Fact] With roughly 6,400 allergists in the U.S. and a median salary of approximately $300,000, this remains one of the more selective and well-compensated medical specialties. [Fact] The growth is driven by rising allergy prevalence — the CDC reports that food allergies in children have increased by 50% since the late 1990s. [Claim] More patients means more demand for specialists, regardless of what AI can do. Climate change is amplifying the demand curve in a less-discussed way: pollen seasons are lengthening and intensifying across most of the U.S., expanding the population of seasonal allergy sufferers who eventually escalate to specialist care.

What Changes — and What Doesn't

By 2028, our projections show AI exposure rising to 53% and automation risk climbing to 25%. [Estimate] That's a meaningful increase, but the nature of the change matters more than the number.

What's changing is the administrative and analytical side of allergy practice. Expect AI to become standard in test interpretation, documentation, and treatment protocol optimization. Allergists who adopt these tools will see more patients, document more efficiently, and potentially catch complex cases earlier. Prior authorization automation in particular is going to reshape the economics of the practice — AI agents that handle insurance back-and-forth save 30-60 minutes per complex case, and complex cases are roughly 20-30% of an allergist's workload.

What's not changing is the clinical core. The physical examination, the procedural skills, the therapeutic relationship, and the emergency response capability — these remain firmly in human territory. An AI can suggest that a patient might benefit from omalizumab based on their IgE profile, but it takes a clinician to evaluate whether that patient is a good candidate considering their complete medical picture, preferences, and insurance situation. The newer biologics — tezepelumab, dupilumab, mepolizumab — bring even more nuance to candidate selection, and the clinical judgment required to optimize across them is firmly within human territory for the foreseeable future.

The Practice Economics Are Shifting

The practice-level economics of allergy and immunology are worth thinking about because they affect career decisions. Private equity has been consolidating allergy practices over the past five years, building regional and multi-state allergy networks that emphasize procedural revenue (immunotherapy, biologics infusions, food challenges) and rely on AI to drive operational efficiency. [Claim] That consolidation is creating two distinct career paths: practice owners who participate in the equity story, and employed allergists who trade ownership upside for stability and lower administrative burden.

Both paths are viable, but they require different skill investments. Practice owners need to understand technology adoption, payer contracting, and operational analytics — areas where AI literacy translates directly into financial outcomes. Employed allergists need to be clinically excellent and procedurally efficient, but they don't need to architect the AI stack themselves. The split is more pronounced than it was a decade ago, and prospective fellows would do well to think about which side they want to land on.

The career advice here is straightforward. If you're an allergist, invest time in learning AI-assisted diagnostic tools and documentation systems. They'll make you faster and more accurate. But don't worry about AI replacing the core of what you do — the data suggests that's a very long way off. Specific actions: pilot an ambient documentation tool for a quarter, evaluate component-resolved diagnostic AI for your most complex food allergy patients, and stay current on biologic indications since that's where prescribing complexity is rising fastest.

For the complete task-level breakdown and year-by-year projections, visit the Allergists occupation page. For comparison with similar medical specialties, see our analysis of dermatologists and general internal medicine physicians.

Update History

• 2026-03-30: Initial publication with 2025 data analysis
• 2026-05-15: Expanded analysis with ambient documentation productivity data, biologic prescribing nuance, PE consolidation trends, and detailed career path differentiation (B2-32 cycle).

Sources

• Anthropic Economic Impacts Report (2025)
• U.S. Bureau of Labor Statistics, Occupational Outlook Handbook
• CDC National Health Statistics Reports

_This analysis was conducted with AI assistance. All data points are sourced from published research and government statistics. For methodology details, see our AI disclosure page._